{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T18:45:30Z","timestamp":1786819530472,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018208","name":"Cure JM Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018208","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rdc.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:15:32Z","timestamp":1757157332000},"page":"655-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Calcinosis in Adult and Juvenile Dermatomyositis"],"prefix":"10.1016","volume":"51","author":[{"given":"Belina Y.","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9197","key":"10.1016\/j.rdc.2025.07.009_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","article-title":"Dermatomyositis","volume":"355","author":"Callen","year":"2000","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.009_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11926-014-0467-y","article-title":"The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis","volume":"16","author":"Hoeltzel","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/BOR.0000000000001036","article-title":"Calcinosis in dermatomyositis","volume":"36","author":"Davuluri","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101768","article-title":"Calcinosis in dermatomyositis: origins and possible therapeutic avenues","volume":"36","author":"Davuluri","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.009_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152104","article-title":"The clinical features of juvenile dermatomyositis: a single-centre inception cohort","volume":"57","author":"Cancarini","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.009_bib8","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.3390\/jcm13123428","article-title":"Calcinosis prevalence in autoimmune connective tissue diseases-a retrospective study","volume":"13","author":"R\u00f3bert","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.rdc.2025.07.009_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1546-0096-12-2","article-title":"Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study","volume":"12","author":"Faller","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib10","first-page":"e195","article-title":"Clinical characteristics of juvenile idiopathic inflammatory myopathy and comparison with adult patients: analysis from a multicentric Cohort in Spain","volume":"28","author":"Loarce-Martos","year":"2022","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.009_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1067\/mpd.2001.112473","article-title":"New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment","volume":"138","author":"Mukamel","year":"2001","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102533","article-title":"Calcinosis biomarkers in adult and juvenile dermatomyositis","volume":"19","author":"Chung","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2019.06.014","article-title":"Long-term outcomes in Juvenile Myositis patients","volume":"50","author":"Tsaltskan","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.009_bib15","first-page":"1250","article-title":"Early abnormal nailfold capillary changes are predictive of calcinosis development in juvenile dermatomyositis","volume":"49","author":"Nozawa","year":"2022","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/rheumatology\/ket360","article-title":"Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis","volume":"53","author":"Shimizu","year":"2014","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1600-0560.1979.tb01175.x","article-title":"Dermatomyositis with universal calcinosis. A histopathological and electron optic study","volume":"6","author":"Nielsen","year":"1979","journal-title":"J Cutan Pathol"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.009_bib18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","article-title":"TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications","volume":"43","author":"Pachman","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.009_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/art.41078","article-title":"Neutrophil extracellular traps in tissue and periphery in juvenile dermatomyositis","volume":"72","author":"Duvvuri","year":"2020","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.009_bib21","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1172\/JCI9799","article-title":"Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo","volume":"105","author":"Olszak","year":"2000","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib22","first-page":"2495","article-title":"Basic calcium phosphate crystals induce monocyte\/macrophage IL-1\u03b2 secretion through the NLRP3 inflammasome in vitro","volume":"186","author":"Paz\u00e1r","year":"2011","journal-title":"J Immunol Baltim Md 1950"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.009_bib23","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/art.24039","article-title":"Childhood myositis heterogeneity collaborative study group. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis","volume":"58","author":"Mamyrova","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.009_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","article-title":"Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy","volume":"33","author":"Kim","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.009_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103061","article-title":"Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis","volume":"138","author":"Duvvuri","year":"2023","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2010.08.038","article-title":"Calcinosis cutis: part I. Diagnostic pathway","volume":"65","author":"Reiter","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.009_bib28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/acr.22672","article-title":"Late nailfold videocapillaroscopy pattern associated with hand calcinosis and acro-osteolysis in systemic sclerosis","volume":"68","author":"Morardet","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.009_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.semarthrit.2010.06.008","article-title":"Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations","volume":"40","author":"Koutaissoff","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2010.134304","article-title":"Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.009_bib31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/vaccines11050898","article-title":"Calcinosis cutis and calciphylaxis in autoimmune connective tissue diseases","volume":"11","author":"Mormile","year":"2023","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.009_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","article-title":"Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis","volume":"150","author":"Valenzuela","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/23971983211053245","article-title":"Subcutaneous calcinosis: is it different between systemic sclerosis and dermatomyositis?","volume":"7","author":"Valenzuela","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.009_bib34","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2020.10.007","article-title":"Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis","volume":"51","author":"Sag","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.009_bib37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM study\u201d)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"27","key":"10.1016\/j.rdc.2025.07.009_bib39","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"issue":"5503","key":"10.1016\/j.rdc.2025.07.009_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.07.009_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/cei.12527","article-title":"Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab\u2019)2 versus Fc sialylation","volume":"178","author":"Schwab","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib44","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","article-title":"Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center","volume":"69","author":"Femia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.009_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-006629","article-title":"Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin","author":"Shahani","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaad.2015.03.047","article-title":"Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis","volume":"73","author":"Galimberti","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jbspin.2012.07.001","article-title":"Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy","volume":"80","author":"Touimy","year":"2013","journal-title":"Jt Bone Spine"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12969-018-0299-9","article-title":"Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis","volume":"16","author":"Orandi","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12969-017-0199-4","article-title":"Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)","volume":"15","author":"Orandi","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib51","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12969-021-00637-8","article-title":"JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology","volume":"19","author":"Ll Wilkinson","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.009_bib53","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.rdc.2025.07.009_bib54","unstructured":"Chinoy H, Krishan A, Sylvestre Y, et al. Baricitinib in the treatment of adult idiopathic inflammatory myopathy: a randomized, treatment delayed-start clinical trial [abstract]. Arthritis Rheumatol 2024; 76 (suppl 9). Available at: https:\/\/acrabstracts.org\/abstract\/baricitinib-in-the-treatment-of-adult-idiopathic-inflammatory-myopathy-a-randomized-treatment-delayed-start-clinical-trial\/. Accessed September 1, 2025."},{"issue":"11","key":"10.1016\/j.rdc.2025.07.009_bib55","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1093\/rheumatology\/keab421","article-title":"Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series","volume":"60","author":"Shneyderman","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.009_bib56","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-023-03170-z","article-title":"Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China","volume":"25","author":"Zhang","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.009_bib59","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1093\/rheumatology\/keae392","article-title":"Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis","volume":"63","author":"Papadopoulou","year":"2024","journal-title":"Rheumatol Oxf Engl"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.009_bib60","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14656566.2024.2392021","article-title":"Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons","volume":"25","author":"Wallwork","year":"2024","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.rdc.2025.07.009_bib61","unstructured":"FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet]. U.S. Food and Drug Administration; 2022. Available at: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed January 16, 2025."},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib62","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib63","first-page":"33","article-title":"Rituximab treatment in adult patients with idiopathic inflammatory myositis: a systematic review and meta-analysis","volume":"31","author":"Rojas","year":"2025","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12969-022-00723-5","article-title":"Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review","volume":"20","author":"Nishi","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2025.07.009_bib65","doi-asserted-by":"crossref","unstructured":"Peskin M, Mostowy M, Velez J, et al. Clinical improvement in early onset interstitial lung disease using rituximab in children with antimelanoma differentiation-associated gene 5-positive juvenile dermatomyositis. J Rheumatol 2023; jrheum.2023-0544. PMID: 37714547. https:\/\/doi.org\/10.3899\/jrheum.2023-0544.","DOI":"10.3899\/jrheum.2023-0544"},{"key":"10.1016\/j.rdc.2025.07.009_bib66","article-title":"Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review","volume":"12","author":"He","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4236\/ojra.2017.71002","article-title":"Effectiveness of rituximab therapy on severe calcinosis in 4 children with juvenile dermatomyositis","volume":"7","author":"Alhemairi","year":"2017","journal-title":"Open J Rheumatol Autoimmune Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.009_bib69","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3899\/jrheum.101321","article-title":"Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry","volume":"38","author":"Bader-Meunier","year":"2011","journal-title":"J Rheumatol"},{"issue":"26","key":"10.1016\/j.rdc.2025.07.009_bib70","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.009_bib71","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.009_bib73","article-title":"Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl","volume":"2020","author":"Sukumaran","year":"2020","journal-title":"Case Rep Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.009_bib74","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib75","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14976","article-title":"The effects of infliximab in treating idiopathic inflammatory myopathies: a review article","volume":"34","author":"Ge","year":"2021","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib78","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","article-title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis","volume":"47","author":"Riley","year":"2008","journal-title":"Rheumatol Oxf Engl"},{"issue":"10416","key":"10.1016\/j.rdc.2025.07.009_bib79","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.009_bib80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.rdc.2025.07.009_bib81","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.009_bib82","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/BOR.0000000000001041","article-title":"From traditional to targeted: the changing trajectory of therapies in dermatomyositis","volume":"36","author":"Castillo","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/10611869409015910","article-title":"Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro","volume":"2","author":"M\u00f6nkk\u00f6nen","year":"1994","journal-title":"J Drug Target"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11926-023-01126-5","article-title":"Calcinosis in juvenile dermatomyositis\u2014epidemiology, pathogenesis, clinical features, and treatment: a systematic review","volume":"26","author":"Gon\u00e7alves J\u00fanior","year":"2024","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13312-020-1712-2","article-title":"Pamidronate in treatment of calcinosis in juvenile dermatomyositis","volume":"57","author":"Giri","year":"2020","journal-title":"Indian Pediatr"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib87","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jbspin.2009.04.011","article-title":"Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate","volume":"77","author":"Slimani","year":"2010","journal-title":"Jt Bone Spine"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.009_bib88","first-page":"135","article-title":"Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis","volume":"28","author":"Marco Puche","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib89","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/14397595.2014.988197","article-title":"Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis","volume":"25","author":"Tayfur","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.009_bib90","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s00296-023-05377-4","article-title":"Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: a real-world experience from a low-middle income country","volume":"44","author":"Mehta","year":"2024","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.009_bib91","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.009_bib92","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J","article-title":"Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study","volume":"43","author":"Bianchi","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.009_bib93","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1310\/hpj5011-975","article-title":"Sodium thiosulfate: calciphylaxis","volume":"50","author":"Generali","year":"2015","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.rdc.2025.07.009_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152306","article-title":"Effectiveness of topical sodium thiosulfate for ectopic calcifications and ossifications. Results of the CATSS-O study","volume":"63","author":"Gauffenic","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.009_bib95","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1111\/ced.13782","article-title":"Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo clinic experience, 2012-2017","volume":"44","author":"Ma","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.009_bib96","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.semarthrit.2017.05.013","article-title":"Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: two cases","volume":"47","author":"Goossens","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib97","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdin.2020.07.002","article-title":"Efficacy of intralesional sodium thiosulfate for the treatment of dystrophic calcinosis cutis: a double-blind, placebo-controlled pilot study","volume":"1","author":"Winter","year":"2020","journal-title":"JAAD Int"},{"issue":"24","key":"10.1016\/j.rdc.2025.07.009_bib98","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.3390\/jcm12247741","article-title":"Systemic sodium thiosulfate as an adjunct treatment in calcinosis: a retrospective study","volume":"12","author":"R\u00f3bert","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.009_bib99","first-page":"1207","article-title":"Intravenous treatment of calcinosis cutis with sodium thiosulfate - a case series","volume":"22","author":"Bruns","year":"2024","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib100","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/bjd.15783","article-title":"Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis","volume":"178","author":"Song","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.009_bib101","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3899\/jrheum.211393","article-title":"Management of calcinosis cutis in rheumatic diseases","volume":"49","author":"Elahmar","year":"2022","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.009_bib102","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.1780381117","article-title":"Treatment of calcinosis with diltiazem","volume":"38","author":"Palmieri","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib103","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/archdermatol.2011.2052","article-title":"Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009","volume":"148","author":"Balin","year":"2012","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.009_bib104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/rheumatology\/39.3.333","article-title":"Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy","volume":"39","author":"Vinen","year":"2000","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib105","first-page":"102","article-title":"Regression of cutis calcinosis with diltiazem in adult dermatomyositis","volume":"15","author":"Abdallah-Lotf","year":"2005","journal-title":"Eur J Dermatol EJD"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.009_bib106","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2133.2001.04153.x","article-title":"An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem","volume":"144","author":"Ichiki","year":"2001","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.009_bib107","first-page":"303","article-title":"Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options","volume":"35","author":"Fredi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"8271","key":"10.1016\/j.rdc.2025.07.009_bib108","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(82)92063-3","article-title":"Verapamil in Duchenne muscular dystrophy","volume":"1","author":"Emery","year":"1982","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.009_bib109","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/rheumatology\/keab810","article-title":"A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis","volume":"61","author":"Chung","year":"2022","journal-title":"Rheumatol Oxf Engl"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:13:54Z","timestamp":1772853234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889857X25000560"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.009","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcinosis in Adult and Juvenile Dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}